Discover
IOVA
Iovance Biotherapeutics, Inc.
5.48
1 x 5.45
1 x 5.50
bid
ask
+
0.46
9.16%
1 @ 04:00 PM
5.49 +0.01 (0.18%)
| Ytd | 100.73% | |
| 1y | 75.08% |
5.02
day range
5.53
1.76
52 week range
5.63
| Open | 5.07 | Prev Close | 5.02 | Low | 5.02 | High | 5.53 | Mkt Cap | 1.96B |
| Vol | 19.99M | Avg Vol | 15.44M | EPS | -0.95 | P/E | -5.77 | Forward P/E | -13.25 |
| Beta | 0.69 | Short Ratio | 7.32 | Inst. Own | 67.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.09 | 200-d Avg | 3.20 | 1yr Est | 8.80 |
| Income Statement | |||
| Total Revenue | 71.43M | ||
| Revenues (USD) | 71.43M | ||
| Cost of Revenue | 42.50M | ||
| Gross Profit | 28.93M | ||
| Operating Expenses | 109.98M | ||
| Research and Development Expense | 62.49M | ||
| Selling, General and Administrative Expense | 38.95M | ||
| Operating Income | -81.04M | ||
| Income Tax Expense | -665.00K | ||
| Net Income | -79.04M | ||
| Net Income Common Stock | -79.04M | ||
| Net Income Common Stock (USD) | -79.04M | ||
| Consolidated Income | -79.04M | ||
| Earnings per Basic Share | -0.19 | ||
| Earnings per Basic Share (USD) | -0.19 | ||
| Earnings per Diluted Share | -0.19 | ||
| Earning Before Interest & Taxes (EBIT) | -79.71M | ||
| Earning Before Interest & Taxes (USD) | -79.71M | ||
| Weighted Average Shares | 418.51M | ||
| Weighted Average Shares Diluted | 418.51M | ||
| Balance Sheet | |||
| Cash and Equivalents | 202.50M | ||
| Cash and Equivalents (USD) | 202.50M | ||
| Investments | 116.94M | ||
| Investments Current | 116.94M | ||
| Trade and Non-Trade Receivables | 81.76M | ||
| Current Assets | 466.50M | ||
| Property, Plant & Equipment Net | 175.78M | ||
| Total Assets | 925.67M | ||
| Debt Current | 3.90M | ||
| Total Debt | 47.78M | ||
| Current Liabilities | 129.42M | ||
| Debt Non-Current | 43.88M | ||
| Total Liabilities | 203.91M | ||
| Accumulated Retained Earnings (Deficit) | -2.85B | ||
| Accumulated Other Comprehensive Income | 12.65M | ||
| Shareholders Equity | 721.75M | ||
| Shareholders Equity (USD) | 721.75M | ||
| Assets Non-Current | 459.16M | ||
| Total Debt (USD) | 47.78M | ||
| Goodwill and Intangible Assets | 269.10M | ||
| Inventory | 58.38M | ||
| Liabilities Non-Current | 74.49M | ||
| Trade and Non-Trade Payables | 37.45M | ||
| Tax Liabilities | 30.61M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 10.42M | ||
| Net Cash Flow from Financing | 94.34M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 33.44M | ||
| Capital Expenditure | -6.61M | ||
| Issuance (Purchase) of Equity Shares | 98.51M | ||
| Net Cash Flow from Investing | 11.39M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 18.00M | ||
| Net Cash Flow from Operations | -72.07M | ||
| Effect of Exchange Rate Changes on Cash | -213.00K | ||
| Share Based Compensation | 11.27M | ||